XML 57 R51.htm IDEA: XBRL DOCUMENT
v3.22.2.2

Financial Assets and Liabilities - Summary of Valuation Processes of Contingent Consideration at Fair Value (Details) - USD ($) $ in Thousands | Sep. 30, 2022 | Jun. 30, 2022
--- | --- | ---
Disclosure Of Financial Instruments [Abstract] |  |
Fair value of cash or stock payable, dependent on achievement of future late-stage clinical or regulatory targets | $ 17,650 | $ 17,827
Fair value of royalty payments from commercialization of the intellectual property acquired | 3,851 | 5,457
Contingent Consideration | $ 21,501 | $ 23,284

X
- References No definition available. + Details
Name: | ifrs-full_DisclosureOfFinancialInstrumentsAbstract
Namespace Prefix: | ifrs-full_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Cash or stock payable at fair value, liabilities. + References No definition available. + Details
Name: | meso_CashOrStockPayableAtFairValueLiabilities
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent considerations. + References No definition available. + Details
Name: | meso_ContingentConsiderations
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Royalty payments at fair value, liabilities. + References No definition available. + Details
Name: | meso_RoyaltyPaymentsAtFairValueLiabilities
Namespace Prefix: | meso_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant